Background: Despite considerable advances in our knowledge
of the pathophysiology of inhalation injury, there are
few specific therapeutic options, and patient care is mainly
supportive. Platelets release growth factors and other immune
system components to start healing process. By using nebulized
Platelet Rich Plasma (PRP), platelets may reduce inflammation
and stimulates bronchial tree healing. However, there are no
clear data supporting or refuting the use of inhaled PRP in
inhalation injury.
Objective: To evaluate the role of nebulized autologous
Platelet Rich Plasma (PRP) in management of Smoke Inhalation
Injury (SII) as early adjuvant therapeutic and prognostic
modality.
Methods: This is prospective study that included 40
patients with burns 25-50% TBSA and have inhalation lung
injury. They were divided into 2 groups; 20 patients received
aerosolized particles of nebulized PRP beside regular regimen.
The other control group included 20 patients and received
regular treatment regimen only.
Results: There was a statistical significant difference
(p<0.01) of biologic changes in upper airway with smoke
injury in study group patients compared to control group
patients who received regular protocol measured at the same
follow-up time interval, relatively same TBSA and initial
bronchoscopy scoring. The mean extubation time was 7±1
days in study group compared to 14±1 days in control group.
Study group less showed shorter hospital stay and less mortality
rate.
Conclusion: The application of aerosolize the PRP solution
in the nebulizer with regular treatment protocol of inhalation
burn patients could be a beneficial therapeutic tool for regenerating
of post burn damaged tracheo-broncho-pulmonary
tree. Further studies on larger patient population with clinical
and pathological evidences are warranted